Inventor · disambiguated record
Michael Roemer
Also filed as: ROEMER MICHAEL
19 granted patents·35 pending applications·10 citations·filing 2019–2025
92Inventor score
Files withIMMATICS BIOTECHNOLOGIES GMBH54
Top patents by PatentIndex Score
54 records- 0198US11732021B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Aug 22, 2023·3 cites·20 claims
- 0298US11655281B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 23, 2023·3 cites·20 claims
- 0398US11655280B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 23, 2023·2 cites·20 claims
- 0498US11603397B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Mar 14, 2023·2 cites·20 claims
- 0591US12318407B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Jun 3, 2025·0 cites·20 claims
- 0691US12290530B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted May 6, 2025·0 cites·20 claims
- 0791US12285443B2Peptides displayed by HLA for use immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Apr 29, 2025·0 cites·20 claims
- 0891US12274716B2Peptides displayed by HLA for use immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Apr 15, 2025·0 cites·20 claims
- 0991US12257269B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Mar 25, 2025·0 cites·20 claims
- 1091US12246039B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Mar 11, 2025·0 cites·20 claims
- 1190US2024239865A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 1290US2024166713A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 1390US2024166717A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 1490US2024239866A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 1590US2024166715A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 1690US2024307447A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 1790US2024269183A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 1890US2024374642A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 1990US2024358757A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2090US2024247045A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2190US2024166716A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2290US2024239867A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2390US2024166714A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2490US2024254191A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2590US2024166712A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2689US2024158460A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 2789US2024117004A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2889US2024067697A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 2989US2024132570A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3089US2024218044A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3189US2024158461A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3289US2024109949A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3389US2024247044A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3489US2024279306A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3589US2024150430A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3689US2024150429A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3789US2024117003A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3889US2024141013A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3988US2024083969A1Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4088US2023331807A1Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4187US11952409B2Amidated peptides and their deamidated counterparts displayed by non-HLA-A*02 for use in immunotherapy against different types of cancers preliminary classIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Granted Apr 9, 2024·0 cites·20 claims
- 4285US12202878B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 21, 2025·0 cites·20 claims
- 4385US12195516B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·20 claims
- 4482US12084486B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 10, 2024·0 cites·20 claims
- 4582US11957716B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Apr 16, 2024·0 cites·27 claims
- 4681US11891427B2Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 6, 2024·0 cites·20 claims
- 4779US12227556B2Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 18, 2025·0 cites·17 claims
- 4878US11433099B2Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 6, 2022·0 cites·27 claims
- 4977US2020040057A1Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Application pending·0 cites
- 5075US11779605B2Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 10, 2023·0 cites·11 claims
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Michael Roemer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →